Drug Screen – Drugs of Abuse (LC/MS)

Detection of amphetamines, benzodiazepines, promazines, barbiturates, opiates, marijuana, and other drug types by liquid chromatography/mass spectrometry. 

Targets include: amphetamine, methamphetamine, MDMA, MDA, bromazepam, demoxepam, diazepam, etizolam, flunitrazepam, lorazepam, midazolam, nordazepam, prazepam, temazepam, acepromazine, 2-(1-hydroxyethyl) promazine sulfoxide (2-HEPS), chlorpromazine, propionylpromazine, promethazine, allobarbital, aprobarbital, phenobarbital, pentobarbital, secobarbital, alfentanil, buprenorphine, butorphanol, codeine, fentanyl, heroin, hydrocodone, levorphanol, morphine, oxymorphone, cannabidiol (CBD), 7-carboxycannabidiol, 7-Nor-7-carboxycannabidiol, tetrahydrocannabinol (THC), delta9-THC, 11-nor-9-carboxy-THC, 11-hydroxy- delta9-THC, carboxy-delta9-THC glucuronide, AM-2201, JWH-122, JWH-200, JWH-210, JWH-081, JWH-019, JWH-203, JWH-250, JWH-015, HU-211, [(±)-CP 47, 497], [(±)-CP 47, 497 C8 Homologue], RCS-4, RCS-8, carisoprodol, cocaine, benzoylecgonine (BEG), GABA, lidocaine, hydroxylidocaine, ketamine, lysergic acid diethylamide, mephedrone, mephenesin, methylone, methylphenidate, naltrexone, pentazocine, phencyclidine, psilocin, psilocybin, pyrovalerone, sertraline, tramadol, trimeprazine, and zolpidem.

A tissue/feed prep fee will be added to tissue and feed specimens. 

One or more of the following: 

• 5 mL serum
• 10 mL urine
• 10 g liver
• 10 g stomach content

Remove serum from red cells and place in an additive free transport tube.

• Serum: plastic or glass tube with no anticoagulant additives. 
• Urine, Liver, Stomach Content: sealed, leak-proof container. A tissue/feed prep fee will be added to tissue and feed specimens. 

Label all samples. Ship overnight on cold packs.

The testing schedule reflects days that extractions are initiated. Samples must be received in the testing section by 3:30 pm the day prior to the scheduled test day, otherwise samples will be held until the next scheduled test day. Turnaround time represents the estimated number of business days needed for complete extraction, sample preparation, instrument analysis, quality review, and data interpretation.
 
Samples deemed suspicious from initial screening will be subject to confirmatory testing. Turnaround time for confirmation can vary and may extend to several weeks depending on the availability of reference standards through approved vendors, the complexity of required analytical and extraction methods, and applicable safety or regulatory considerations. In some cases, consultation may be required prior to proceeding with confirmation, and confirmation testing may be delayed or declined based on these factors.
 
Quantitation of positive samples can be performed for an additional fee and may extend turnaround times.

A tissue/feed prep fee will be added to tissue and feed specimens.